login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Boston Scientific launches Ingenio and Advantio family of pacemakers in Europe


Wednesday, 11 Apr 2012 10:29

Boston Scientific has announced CE mark approval and European market launch of its Ingenio and Advantio pacemakers and  Invive cardiac resynchronisation therapy pacemakers (CRT-P). Marc Burban performed one of the first implants of the Ingenio on the first week of April at the Nouvelles Cliniques Nantaises in Nantes, France. 


“The Ingenio device enables physicians to treat pacemaker patients with an advanced and comprehensive set of therapies,” said Burban. “The new RightRate pacing is easy to optimise and is designed to provide needed heart rates for patients to help them feel less fatigued during physical activity.”

“The Ingenio family of pacemakers represents a significant investment in long-term innovation for pacing technologies and defines a new era of pacing for our company,” said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group. “In addition, we expect to launch a series of devices with expanded capabilities, that would include remote monitoring, advanced heart failure diagnostics and compatibility with magnetic resonance imaging systems - all designed to provide innovative new features for patient health and well-being.”


The Ingenio and Advantio pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence. RightRate employs Boston Scientific’s minute ventilation sensor, the only sensor clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings.


The Ingenio and Advantio pacemakers are currently under review by the US Food and Drug Administration (FDA), and are currently not available for sale in the United States.




Add New Comment

Most popular


Baroreflex neuromodulation therapy shows positive outcomes in heart failure treatment
Monday, 23 Mar 2015
The first randomised controlled trial studying carotid baroreflex stimulation for heart failure treatment has shown the therapy is safe and has demonstrated improvement in functional status, quality ... Baroreflex neuromodulation therapy shows positive outcomes in heart failure treatment

Boston Scientific receives FDA approval for Watchman left atrial appendage closure device
Monday, 16 Mar 2015
The device offers an alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation. Boston Scientific receives FDA approval for Watchman left atrial appendage closure device

Long-term sustained weight loss associated with significant reduction in AF burden
Friday, 27 Mar 2015
The first study investigating the long-term effects of weight loss and the degree of weight fluctuation on atrial fibrillation (AF) burden has found that obese patients with this arrhythmia who lost ... Long-term sustained weight loss associated with significant reduction in AF burden

Features


SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea
Tuesday, 24 Mar 2015
Martin Cowie (Imperial College London, London, UK) is the principal investigator of the SERVE-HF study, which is assessing the use of adaptive servo-ventilation (PaceWave, ResMed) in chronic heart ... SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea

A new study explores heart failure treatment with vagal nerve stimulation
Thursday, 12 Mar 2015
Albert Hagège (Georges Pompidou European Hospital in Paris, France), principal investigator of Vanguard, a new study exploring the safety and efficacy of vagal nerve stimulation in heart failure ... A new study explores heart failure treatment with vagal nerve stimulation

Profiles


Hung-Fat Tse
Tuesday, 03 Feb 2015
While Hung-Fat Tse’s initial research interests focused on device therapy for cardiac arrhythmias, ... Hung-Fat Tse

Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions